Skip to main content
OpenTrials
Completed

NCT Number: NCT02261090

Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers

Study to compare the oral bioavailability of seven prototype slow-release formulations to immediate-release tablets

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

21 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All participants in the study should be healthy males
  • Participants should be ranging from 21 to 50 years of age
  • Body mass index (BMI) within 18.5 to 29.9 kg/m2
  • In accordance with Good Clinical Practice and the local legislation all volunteers will have given their written informed consent prior to admission to the study

Exclusion criteria

  • Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (> 24:00 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study or during the study
  • Use of any drugs which might influence the results of the trial up to 7 days prior to enrolment in the study or during the study
  • Participation in another trial with an investigational drug (≤ two months prior to administration or during the trial)
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking on in-house trial days
  • Alcohol abuse (> 60 g/day)
  • Drug abuse
  • Blood donation (≥ 100 mL within four weeks prior to administration or during the trial)
  • Any laboratory value outside the clinically accepted reference range
  • Excessive physical activities within the last week before the trial or during the trial
  • Hypersensitivity to pramipexole, or other dopamine agonists
  • Supine blood pressure at screening of systolic < 110 mmHg and diastolic < 60 mmHg
  • A haemoglobin value at screening of less than 13.5 g/dl (usual lower limit of normal for males: 12.6 g/mL)
  • Subjects involved in passenger transport or operation of dangerous machines

Treatment and study plan

Formulation B: Pramipexole Slow release (SR) tablet

Drug

Formulation C: Pramipexole Slow release tablet

Drug

Formulation D: Pramipexole Slow release tablet

Drug

Formulation E: Pramipexole Slow release tablet

Drug

Formulation F: Pramipexole Slow release tablet

Drug

Formulation G: Pramipexole Slow release tablet

Drug

Formulation H: Pramipexole Slow release tablet

Drug

Pramipexole immediate release (IR) tablets

Drug

Primary outcomes

  1. Plasma total exposure (AUCτ,ss)

    Time frame: up to 168 hours after each drug administration

  2. Urine total exposure (Aeτ,ss)

    Time frame: up to 168 hours after each drug administration

  3. Plasma maximum exposure (Cmax,ss)

    Time frame: up to 168 hours after each drug administration

  4. Plasma minimum exposure (Cmin,ss)

    Time frame: up to 168 hours after each drug administration

  5. Plasma average concentration (Cavg)

    Time frame: up to 168 hours after each drug administration

  6. Plasma peak to trough fluctuation (PTF)

    Time frame: up to 168 hours after each drug administration

Secondary outcomes

  1. AUC0-6,11 for the immediate release (IR) formulation

    Time frame: day 7 of visit 2

  2. Cmax for the IR formulation

    Time frame: up to 168 hours after drug administration in visit 2

  3. Cmin for the IR formulation

    Time frame: up to 168 hours after drug administration in visit 2

  4. tmax for the IR formulation

    Time frame: up to 168 hours after drug administration in visit 2

  5. Urinary excretion (Ae) for the IR formulation

    Time frame: up to 168 hours after drug administration in visit 2

  6. tmax,4 for the SR formulation

    Time frame: up to 96 hours after drug administration in visit 3-5, 7 and 9

  7. t1/2,4 for the SR formulation

    Time frame: up to 96 hours after drug administration in visit 9

  8. Urinary excretion (Ae) for the SR formulation

    Time frame: up to 168 hours after drug administration

  9. Number of subjects with adverse events

    Time frame: up to 8 days after last drug administration

  10. Number of subjects with clinically significant findings in laboratory tests

    Time frame: up to 8 days after last drug administration

  11. Number of subjects with clinically significant findings in vital signs

    Time frame: up to 8 days after last drug administration

    blood pressure, pulse rate

  12. Assessment of global tolerability by investigator on a 5-point scale

    Time frame: at the end of each of the visits 2 to 9

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A Multiple Dose Seven-way Cross-over Formulation-finding Study Comparing the Oral Bioavailability of Seven Prototype Slow-release Formulations With 0.75 mg Pramipexole (Four Days Each) to Immediate-release Tablets at Steady State in Healthy Male Volunteers

Important dates

Study start
2004
Primary completion
2004
First posted
Oct 10, 2014
Registry last updated
Oct 10, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.